Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography

Cuisinaud, G.; Ferry, N.; Seccia, M.; Bernard, Nicole F.; Sassard, J

doi:10.1016/s0378-4347(00)81142-1

Cited by 38 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…method of Cuisinaud et al (1980). The assay was linear for all compounds up to 50 ,ug ml-' plasma and up to 150 p,g ml-urine.…”

Section: Assay Methodsmentioning

confidence: 94%

See 1 more Smart Citation

The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Ferry¹,

Bernard²,

Pozet³

et al. 1991

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

1. Ten healthy subjects received two treatments: a single 1 g oral dose of nalidixic acid (NA) followed 1 h later by either an infinitesimal dilution of the drug (NA 7CH) or by succussed water which served as placebo. The study was repeated 18 months later in 10 different subjects. 2. A further 10 healthy subjects received three treatments: a single 100 mg oral dose of atenolol (AT) followed 3 h later by either placebo or a dilution of AT (AT 7CH) or of bisoprolol (BI 7CH). The homoeopathic preparations were administered by the sublingual route. 3. In the first NA experiment NA 7CH significantly shortened the elimination half‐life of NA from 8.6 +/‐ 2.2 (placebo) to 6.4 +/‐ 1.6 h (NA 7CH). In the second NA experiment none of the pharmacokinetic parameters was modified significantly by the administration of NA 7CH. Neither AT 7CH nor BI 7CH modified the pharmacokinetics of AT.

show abstract

“…method of Cuisinaud et al (1980). The assay was linear for all compounds up to 50 ,ug ml-' plasma and up to 150 p,g ml-urine.…”

Section: Assay Methodsmentioning

confidence: 94%

“…Nalidixic acid Plasma and urine samples were assayed for NA, HNA and CNA by the h.p.l.c. method of Cuisinaud et al (1980). The assay was linear for all compounds up to 50 ,ug ml-' plasma and up to 150 p,g ml-urine.…”

Section: Assay Methodsmentioning

confidence: 94%

The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Ferry¹,

Bernard²,

Pozet³

et al. 1991

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…(ii) Analysis of human, baboon, and rabbit plasma by Roche. The concentrations of total CRO were determined by a modified chromatographic method described by Cuisinaud et al (34). The HPLC system consisted of a model 6000 A pumping system, an automatic sample injector (model 710A), and a model 440 dual-channel UV detector at 270 nm (Waters Associates, Milford, MA).…”

Section: Methodsmentioning

confidence: 99%

Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions

Gaudin

Désiré

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. This article presents all available data on the nonparenteral absorption of ceftriaxone in humans and animals, including unpublished work carried out by F. Hoffmann-La Roche (Roche) in the 1980s and new data from preclinical studies with rabbits, and discusses the importance of these data for the development of noninjectable formulations for noninvasive treatment. The combined results indicate that the rectal absorption of ceftriaxone is feasible and likely to lead to a bioavailable formulation that can reduce treatment delays in neonatal sepsis. A bile salt, chenodeoxycholate sodium salt (Na-CDC), used as an absorption enhancer at a 125-mg dose, together with a 500-mg dose of ceftriaxone provided 24% rectal absorption of ceftriaxone and a maximal plasma concentration of 21 µg/ml with good tolerance in human subjects. The rabbit model developed can also be used to screen for the bioavailability of other formulations before assessment in humans.

show abstract

“…By using a specific high pressure liquid chromatographic technique (Cuisinaud et al, 1980) we could demonstrate, in normal humans having received single and repeated oral doses of NA, that CNA accounted for 25% of the total urinary NA and metabolites although it was not detectable in plasma (Ferry et al, 1981). This finding suggests that CNA could be, at least partially, formed within the kidney.…”

Section: Introduction Methodsmentioning

confidence: 99%

Nalidixic acid kinetics in renal insufficiency.

Cuisinaud¹,

Ferry²,

Pozet³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 A pharmacokinetic study of nalidixic acid (NA) and metabolites was carried out in 23 patients with differing renal function so as to determine the influence of renal insufficiency on the excretion and biotransformation rate of this antibacterial agent. Plasma and urine concentration of NA and of its 7-hydroxy (HNA) and 7-carboxy (CNA) derivatives were measured after a single oral administration. 2 Renal insufficiency did not markedly affect the renal clearance of NA while it significantly decreased the elimination rate of HNA, a compound which largely excreted into the urine. 3 Interestingly, CNA which could never be detected in the plasma of patients with normal renal function appeared in that of patients with renal insufficiency. Plasma concentrations of CNA and creatinine were positively related, and the amount of urinary CNA increased with the renal impairment.4 These results suggest that HNA can still be biotransformed into CNA by the impaired kidney. Since CNA cannot be easily excreted in the urine of patients with renal insufficiency it is hypothesized that this compound back diffuses into the plasma. 5 Finally, the study of the urinary concentrations of NA and metabolites shows that a standard NA dosage can be used, at least in patients with mild renal insufficiency.

show abstract

Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography

Cited by 38 publications

References 10 publications

The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions

Nalidixic acid kinetics in renal insufficiency.

Contact Info

Product

Resources

About